Gene-Modified Cell Therapy
Gene-modified cell therapies are a remarkable advancement in the fight against cancer. Landmark approvals of Kymriah and Yescarta in 2017 set the stage for rapid growth in the sector and just a few short years later, over 400 clinical trials are underway. As the industry continues to move at an unprecedented speed, we provide Solutions that help immune cell therapy developers and manufacturers accelerate their time to market and lower their COGs. These Solutions are specifically designed to address the unique challenges and goals of CAR-T R&D, process development and manufacturing.
Ensure: Overcome obstacles from concept to clinic by mitigating cell, donor and process variability with automation and control
Enhance: Gain process understanding by integrating upstream, downstream, and data analysis processes and rapidly optimize CPPs to achieve target cell product quality
Excel: Successfully bring life-saving immune cell therapies to patients faster by streamlining workflows throughout R&D, process development, and manufacturing
Explore how scale-down models can facilitate the development of process knowledge to set the stage for seamless scale-up.
Pure, safe, and consistent, USP-NF compliant Recombumin® recombinant human albumins support gene-modified cell therapies from R&D to in-human appl...
Enhance Your Immune Cell Activation and Expansion With Proven Performance, Purity, and Sterility
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.